RECURSION PHARMACEUTICALS, INC. 8-K

What Happened

• On May 6, 2026, Recursion Pharmaceuticals, Inc. (RXRX) announced its results of operations and financial condition for the quarter ended March 31, 2026 (Item 2.02) via a press release furnished as Exhibit 99.1 to the 8-K.
• On the same day the company updated its corporate presentation and posted it to the investor section of its website (Item 7.01); that presentation is included as Exhibit 99.2 to the filing.

Key Details

• Filing date: May 6, 2026 (Current Report on Form 8-K).
• Subject: Results of operations and financial condition for Q1 (period ended March 31, 2026).
• Exhibits included: Exhibit 99.1 (press release), Exhibit 99.2 (earnings/corporate presentation), and Exhibit 104 (Inline XBRL cover page).
• Disclosure types: Item 2.02 (results announced) and Item 7.01 (Regulation FD — investor presentation posted).

Why It Matters

• The 8-K signals that Recursion has released its quarterly financial results and refreshed investor materials; these documents are the primary sources for revenue, cash position, operating results, and any company commentary on performance or outlook.
• Retail investors should review the attached press release (Exhibit 99.1) and the updated presentation (Exhibit 99.2) for the specific financial figures, operational highlights, and management commentary before making investment decisions.